A Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of AG2304T and AG2304R

Phase 3

Not yet recruiting

• Conditions: Hypercholesterolemia
• Interventions: Drug: AG2304T; Drug: AG2304R

• Registration Number: NCT06717360
• Lead Sponsor: Ahn-Gook Pharmaceuticals Co.,Ltd

Brief Summary

A Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of AG2304T and AG2304R in Patients with Primary Hypercholesterolemia

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2024-11-28
• Status Verified: 2024-12
• Study First Submitted QC: 2024-12-03
• Last Update Submitted: 2024-12-03
• Study First Posted: 2024-12-05
• Last Update Posted: 2024-12-05
• Study Start: 2025-06
• Primary Completion: 2027-06
• Study Completion: 2027-06

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 140

Inclusion Criteria

• Adults aged 19-80
• Patients with primary hypercholesterolemia
• Those who voluntarily written consent to participate in this clinical trial

Exclusion Criteria

• The subject not meet the specified LDL-C level
• Other exclusions applied

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
AG2304T	AG2304T	-
AG2304R	AG2304R	-

Primary Outcome Measures

Name	Time	Method
LDL-C level	8 weeks